Home > Oncology > ASCO 2021 > Genitourinary Cancers > VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC

VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC

Presented By
Dr Michael Morris, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO 2021
Trial
Phase 3, VISION
Addition of 177Lu-PSMA-617 radioligand therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improved survival, according to results from the randomised, phase 3 VISION trial. Despite recent therapeutic advances, mCRPC remains invariably fatal. Prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC lesions. The targeted radioligand 177Lu-PSMA-617 delivers β-particle radiation to PSMA-expressing cells and the surrounding microenvironment [1]. The VISION trial (NCT03511664) is an international, randomised, open-label, phase 3 study evaluating 177Lu-PSMA-617 in men with PSMA-positive mCRPC, previously treated with next-generation androgen receptor signalling inhibition and 1–2 taxane regimens. The trial randomised...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on